Desjardins Capital

Desjardins Capital is the private equity and venture capital arm of Mouvement des caisses Desjardins, based in Quebec, Canada. It provides growth capital, mezzanine, and select debt financing to early-stage through mature companies across industrial, manufacturing, technology, and service sectors, with emphasis on health care, life sciences, and biotechnology. The firm also supports cooperatives, including worker-owned and housing cooperatives, and network cooperatives, financing development, acquisitions, expansions, and succession plans. It primarily invests in Quebec and surrounding regions, and can finance growth, acquisitions, management buyouts, and modernization. Investments may be equity or debt, including unsecured loans, with instruments ranging from senior debt to equity, and tenures typically five to eight years for equity and three to five years for debt. The firm often takes minority stakes with board participation. It does not invest in natural resource exploration or financial services. Desjardins Capital traces its roots to 1974 and operates within the Desjardins Group.

Daniel Archambault

Investment Manager

Nathalie Bernard

COO

Eric Bolduc

Investment Director

Jean-Yves Bourgeois

Managing Director and Group Head, Capital Markets

Jean-Philippe Bujold

Investment Manager

Past deals in EEG

NeuroServo

Seed Round in 2023
NeuroServo is a developer of innovative medical technology, specializing in the creation of VEEGix, a miniaturized prefrontal electroencephalogram (EEG) device. Designed for use in emergency situations within Intensive Care Units, VEEGix significantly reduces the time required for brainwave analysis and pathology detection compared to traditional EEG systems, which necessitate the involvement of specialized technicians and neurologists. This device can be installed by nursing staff and delivers interpretable brain status information within a minute, making it invaluable for urgent scenarios where rapid intervention is crucial. VEEGix is intended for use as an emergency EEG to address time-sensitive conditions, as well as a cerebral monitoring tool for patients under sedation, thereby enhancing patient care and potentially mitigating the risk of permanent brain damage.

NeuroServo

Seed Round in 2018
NeuroServo is a developer of innovative medical technology, specializing in the creation of VEEGix, a miniaturized prefrontal electroencephalogram (EEG) device. Designed for use in emergency situations within Intensive Care Units, VEEGix significantly reduces the time required for brainwave analysis and pathology detection compared to traditional EEG systems, which necessitate the involvement of specialized technicians and neurologists. This device can be installed by nursing staff and delivers interpretable brain status information within a minute, making it invaluable for urgent scenarios where rapid intervention is crucial. VEEGix is intended for use as an emergency EEG to address time-sensitive conditions, as well as a cerebral monitoring tool for patients under sedation, thereby enhancing patient care and potentially mitigating the risk of permanent brain damage.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.